Last updated: September 8, 2026
Polymyxin B sulfate and trimethoprim ophthalmic solution is an established topical antibacterial combination sold in the United States under the Polytrim brand and through generic equivalents. Its commercial opportunity is not based on new-molecule exclusivity. It is based on reliable sterile manufacturing, preservative optimization, differentiated packaging, supply continuity, and targeted ophthalmic distribution.
The reference product is an aqueous ophthalmic solution containing polymyxin B sulfate at 10,000 units/mL and trimethoprim sulfate equivalent to 1 mg/mL of trimethoprim. The principal listed excipients are benzalkonium chloride, sodium chloride, dibasic sodium phosphate, hydrochloric acid and/or sodium hydroxide for pH adjustment, and purified water.[1]
What is the FDA regulatory status of polymyxin B sulfate and trimethoprim?
Polymyxin B sulfate and trimethoprim ophthalmic solution is an FDA-approved prescription ophthalmic antibacterial. The reference product is associated with NDA 050783 and is indicated for the treatment of external infections of the eye and surrounding structures caused by susceptible organisms.[1]
| Attribute |
Product profile |
| Active ingredients |
Polymyxin B sulfate and trimethoprim sulfate |
| Dosage form |
Sterile ophthalmic solution |
| Route |
Topical ocular |
| Reference product |
Polytrim ophthalmic solution |
| Reference NDA |
050783 |
| Typical strength |
Polymyxin B sulfate 10,000 units/mL; trimethoprim 1 mg/mL |
| Regulatory pathway for generics |
ANDA under Section 505(j) |
| Product class |
Small-molecule topical antibacterial combination |
| Biosimilar pathway |
Not applicable |
| Primary commercial barriers |
Sterility, preservative performance, container closure, supply reliability, and ophthalmic quality |
The product is not a biologic and does not qualify for biosimilar competition. Generic applicants generally pursue an abbreviated new drug application rather than a 351(k) biosimilar application.[2]
When does polymyxin B sulfate and trimethoprim lose exclusivity?
The product is a mature anti-infective with no meaningful new-molecule exclusivity remaining. Commercial protection depends on generic competition, FDA approval requirements, manufacturing quality, and customer access rather than on a remaining branded exclusivity period.
What is the Orange Book status?
The FDA Orange Book is the controlling source for current patent and exclusivity listings. Mature ophthalmic antibacterial products commonly have no active Orange Book patent protection when the reference product has been marketed for decades. The relevant commercial conclusion is that an applicant should not assume that a formulation or method-of-use patent blocks an ANDA unless the patent is specifically listed against the reference NDA.[3]
For this product category:
- The active ingredients are old and widely characterized.
- The branded product does not depend on a new chemical entity patent.
- Paragraph IV risk is likely to be limited to any later-listed formulation, dosage-form, or method-of-use patent.
- Patent protection around excipient combinations would need to satisfy novelty, nonobviousness, written-description, enablement, and FDA listing requirements.
- Trade secrets may protect manufacturing controls even when patents do not.
What patents protect polymyxin B sulfate and trimethoprim ophthalmic products?
The strongest practical patent opportunity is not the basic combination of polymyxin B sulfate and trimethoprim. That combination is established, and broad composition claims would face substantial prior-art exposure.
Potential claim areas include:
| Claim area |
Commercial value |
Patent risk |
| Basic polymyxin B/trimethoprim combination |
Low |
High obviousness and prior-art risk |
| Aqueous formulation with defined pH and osmolality |
Moderate |
Moderate to high |
| Preservative-free multidose system |
High if clinically differentiated |
Moderate |
| Low-irritation preservative system |
Moderate |
Moderate |
| Unit-dose packaging and oxygen control |
Moderate |
Moderate |
| Improved polymyxin B stability |
Moderate to high |
Moderate |
| Manufacturing process controlling potency or impurities |
Moderate |
Moderate |
| Pediatric dosing or administration method |
Low to moderate |
High method-of-use risk |
| Treatment of a narrowly defined resistant organism |
Low to moderate |
Clinical and written-description risk |
A formulation patent would need more than a routine substitution of excipients. A defensible claim may require unexpected stability, improved tolerability, reduced preservative exposure, lower particulate formation, or a clinically meaningful dosing advantage.
What excipients are used in Polytrim ophthalmic solution?
The reference formulation uses a conventional preserved aqueous system.[1]
| Excipient |
Likely function |
| Benzalkonium chloride |
Antimicrobial preservative |
| Sodium chloride |
Tonicity adjustment |
| Dibasic sodium phosphate |
Buffering capacity |
| Hydrochloric acid and/or sodium hydroxide |
pH adjustment |
| Purified water |
Vehicle |
Benzalkonium chloride, or BAK, is commercially useful because it is effective at low concentration and compatible with many multidose ophthalmic packages. It also creates the principal formulation opportunity. Repeated exposure to BAK can raise tolerability concerns, particularly in patients with ocular-surface disease, chronic topical therapy, contact-lens use, or repeated courses of treatment.[4]
The commercial objective is therefore not simply to reproduce the reference excipient list. It is to provide equivalent antibacterial performance with a measurable usability advantage.
What excipient strategies can differentiate a generic product?
Preservative-free unit-dose packaging
A preservative-free presentation could target pediatric use, short-term intensive therapy, patients with ocular-surface sensitivity, and settings where preservative exposure is commercially relevant. The main disadvantages are higher packaging cost, increased filling complexity, more material consumption, and possible adherence challenges.
Unit-dose packaging also creates a larger waste stream and may be less attractive to pharmacies unless supported by clear patient or prescriber demand.
Alternative multidose preservative systems
A multidose product using an alternative preservative or preservative-releasing container could lower BAK exposure while preserving convenience. Candidate approaches include oxidative preservatives, polyquaternium systems, stabilized oxychloro complexes, or specialized valve-based containers.
Each option requires compatibility testing against:
- Polymyxin B potency and molecular integrity
- Trimethoprim stability
- Container adsorption
- Extractables and leachables
- Preservative effectiveness
- Droplet size and delivered volume
- Ocular irritation
- Microbial ingress during in-use storage
A formulation that reduces BAK but compromises preservative efficacy is unlikely to provide a viable regulatory or commercial advantage.
Buffer and pH optimization
The formulation must balance comfort, active-ingredient stability, and preservative performance. Phosphate buffering is familiar and inexpensive, but a lower-buffer or alternative-buffer system may improve tolerability or reduce interaction with packaging materials.
The product should be evaluated across the proposed shelf-life period for:
- pH drift
- Osmolality
- Trimethoprim degradation
- Polymyxin B potency
- Visible and subvisible particles
- Color and clarity
- Preservative concentration
- Container closure integrity
Tonicity and viscosity adjustment
Sodium chloride provides a straightforward tonicity adjustment. A modest viscosity increase could extend ocular residence time and reduce drainage, but it may also produce transient blurred vision, affect drop size, or complicate dispensing.
Viscosity differentiation is more commercially credible when tied to a specific use case, such as reduced dosing frequency or improved retention. Without a dosing advantage, the additional excipient may increase development risk without creating a defensible market position.
Packaging-led excipient strategy
The container can be as important as the liquid formulation. Relevant options include:
- Low-sorption polyethylene or polypropylene bottles
- Drop-control systems that reduce dose variability
- Multidose preservative-free valves
- Unit-dose blow-fill-seal containers
- Light-protective packaging
- Tamper-evident closures
- Child-resistant secondary packaging where required
Packaging claims may support a broader product strategy, but they do not automatically create patentable subject matter. The commercial value comes from lower contamination risk, improved dose delivery, or improved user experience.
What are the main generic entry opportunities?
The base opportunity is a conventional ANDA for an ophthalmic solution that matches the reference product in active ingredients, strength, dosage form, route, and key quality attributes. A standard generic is likely to compete primarily on price, wholesaler access, and supply reliability.
A differentiated product can pursue several segments:
| Opportunity |
Buyer or user |
Commercial rationale |
| Standard generic solution |
Retail pharmacies and wholesalers |
Lowest development complexity |
| Preservative-reduced product |
Ophthalmologists and ocular-surface patients |
Tolerability positioning |
| Preservative-free unit dose |
Pediatrics, hospitals, sensitive patients |
Avoids BAK exposure |
| Premium multidose system |
Specialty ophthalmology |
Convenience and contamination control |
| Institutional supply |
Hospitals and ambulatory surgery centers |
Contract and shortage resilience |
| Regional private label |
Pharmacy chains and distributors |
Margin and channel control |
| International ophthalmic product |
Local marketing partners |
Regulatory and manufacturing leverage |
The highest-value commercial path is usually a two-tier portfolio: a low-cost standard generic for volume and a differentiated presentation for margin.
What FDA requirements apply to an ANDA?
An ANDA applicant must establish pharmaceutical equivalence and bioequivalence under the applicable FDA standards. For a topical ophthalmic solution, the development program also depends heavily on product quality and microbiological control.[2]
Key development areas include:
- Active-ingredient identity and assay.
- Polymyxin B potency and component characterization.
- Trimethoprim assay and degradation profile.
- pH and osmolality.
- Sterility.
- Preservative effectiveness.
- Particulate matter.
- Container closure integrity.
- Extractables and leachables.
- Stability under long-term and accelerated conditions.
- In-use stability after opening.
- Drop size and delivered volume.
Polymyxin B is a mixture of related components rather than a single uniform small molecule. That creates a higher analytical burden than a simple single-component ophthalmic solution. The applicant must control potency and compositional consistency across batches.
What generic launch risks exist?
The largest risks are operational rather than patent-based.
Sterility and microbial control
A sterile ophthalmic product must maintain microbiological quality through manufacturing, packaging, shipping, and in-use handling. A contamination event can cause recalls, warning letters, or loss of customer confidence.
Polymyxin B supply
Polymyxin B sulfate is an older active ingredient with specialized production and testing requirements. Supplier qualification, dual sourcing, impurity control, and API continuity can determine whether a low-margin product remains commercially viable.
Preservative failure
A product may meet initial specifications but fail preservative effectiveness or in-use testing. This risk is particularly relevant for alternative preservative systems and preservative-free multidose devices.
CMC comparability
A formulation that is chemically similar to the reference product can still encounter regulatory questions if excipient levels, pH, viscosity, packaging, or impurity profiles differ materially.
Channel pricing
Mature ophthalmic antibiotics are exposed to aggressive generic pricing, wholesaler consolidation, pharmacy purchasing pressure, and periodic supply shortages. A product without a packaging, supply, or service advantage may become economically unattractive after launch.
Which companies are challenging the reference product?
Generic competition is expected from ANDA holders rather than biosimilar developers. The relevant competitive set includes established generic ophthalmic manufacturers, specialty sterile-product companies, contract manufacturers, and regional pharmaceutical suppliers.
A reliable competitor analysis should distinguish among:
- Approved ANDA holders
- Applicants with tentative approval
- Authorized generic suppliers
- Private-label distributors
- Companies with sterile ophthalmic manufacturing capacity
- Suppliers with integrated polymyxin B or trimethoprim sourcing
The FDA Orange Book and Drugs@FDA provide the principal public sources for approved products, reference-product designations, and patent or exclusivity information.[3,5]
What patent litigation and Paragraph IV risks affect the product?
A Paragraph IV certification becomes relevant only if a listed patent remains associated with the reference NDA. For a mature product such as polymyxin B sulfate and trimethoprim ophthalmic solution, the principal risk is usually not a basic active-ingredient patent. It is a later patent directed to:
- A new formulation
- A preservative-free system
- A multidose container
- A stability improvement
- A narrow method of treatment
- A specific dosing regimen
The litigation exposure should be assessed patent by patent. A Paragraph IV notice can trigger a 45-day period for the patent holder to file suit, potentially creating a 30-month stay under the Hatch-Waxman framework.[6] If no relevant listed patent exists, the applicant’s principal launch risks remain FDA review, manufacturing readiness, and commercial contracting.
No biosimilar litigation framework applies because the product is a small-molecule antibacterial combination.
How strong is the patent estate for polymyxin B sulfate and trimethoprim?
The estate is weak for the core combination and potentially moderate for a technically differentiated formulation.
| Estate component |
Relative strength |
Assessment |
| Active ingredients |
Low |
Mature compounds and extensive prior art |
| Core ophthalmic combination |
Low |
Established clinical and commercial use |
| Standard aqueous vehicle |
Low |
Routine formulation technology |
| BAK-preserved formulation |
Low |
Conventional excipient approach |
| Preservative-free multidose system |
Moderate |
Depends on device and performance data |
| Stability-enhanced formulation |
Moderate |
Requires unexpected technical effect |
| Manufacturing process |
Moderate |
Stronger if process results are difficult to reproduce |
| Brand and channel access |
Commercial, not patent |
May matter more than patent protection |
Trade secrets covering sterile filling, polymyxin B handling, impurity control, and container compatibility may provide greater practical value than broad composition patents.
How does polymyxin B sulfate and trimethoprim compare with competing ophthalmic antibiotics?
Polymyxin B/trimethoprim competes with topical agents such as trimethoprim-containing combinations, aminoglycosides, fluoroquinolones, and other ophthalmic antibacterials.
| Product class |
Main advantage |
Main limitation |
| Polymyxin B/trimethoprim |
Established combination and broad topical use |
Mature market and limited patent protection |
| Aminoglycoside ophthalmics |
Familiar low-cost products |
Ocular irritation and resistance considerations |
| Fluoroquinolone ophthalmics |
Broad antibacterial coverage and strong institutional use |
Greater stewardship pressure and generic price competition |
| Single-agent trimethoprim products |
Simpler formulation |
Narrower antibacterial spectrum |
| Newer branded ophthalmic antibiotics |
Potential dosing or tolerability advantages |
Higher price and patent exposure |
The product is best positioned where prescribers value a familiar, low-cost topical combination for susceptible external ocular infections.
What are the licensing and commercial partnership opportunities?
Licensing is more likely to involve manufacturing, distribution, packaging technology, or regional rights than a foundational drug patent.
Potential transactions include:
- Regional marketing licenses
- Contract manufacturing agreements
- Private-label supply
- Co-development of preservative-free presentations
- In-licensing of multidose container technology
- Dual-source API agreements
- Hospital and government procurement contracts
- Authorized-generic arrangements
A differentiated formulation can support a higher-value partnership if it demonstrates lower preservative exposure, longer in-use stability, reduced waste, or improved delivery performance. A standard generic is more likely to attract supply and distribution partners than a traditional royalty-based license.
Key Takeaways
- Polymyxin B sulfate and trimethoprim ophthalmic solution is a mature FDA-approved antibacterial combination with limited remaining exclusivity value.
- The reference formulation is an aqueous, BAK-preserved ophthalmic solution.
- The strongest commercial opportunity is a combination of standard generic volume and differentiated preservative-free or low-irritation packaging.
- Core active-ingredient and combination patents are unlikely to provide meaningful protection.
- Formulation, container, stability, and manufacturing-process patents may have moderate value if supported by unexpected technical results.
- Biosimilar competition is not relevant because the product is a small-molecule drug.
- The main launch risks are sterile manufacturing, polymyxin B supply, preservative performance, CMC review, and generic price compression.
- Manufacturing reliability and channel access may create more durable commercial advantage than patent ownership.
FAQs
Is polymyxin B sulfate and trimethoprim available as a preservative-free product?
The reference Polytrim formulation is preserved with benzalkonium chloride. A preservative-free commercial opportunity would require unit-dose packaging or a validated preservative-free multidose delivery system.
Can an applicant obtain a patent on a new Polytrim formulation?
Yes, but a patent would need claims that are novel and nonobvious. A routine change in buffer, tonicity agent, or preservative is unlikely to provide strong protection without unexpected stability, tolerability, or delivery results.
Is polymyxin B sulfate difficult to formulate?
It can be more technically demanding than a simple single-molecule ophthalmic product because polymyxin B is a mixture of related components. Potency, impurity control, stability, and supplier consistency require close monitoring.
Is Polytrim subject to biosimilar competition?
No. Polymyxin B sulfate and trimethoprim ophthalmic solution is a small-molecule drug. Competition proceeds through generic ANDAs, not the biosimilar pathway.
What is the most attractive commercial differentiation?
The strongest differentiation is likely to come from reduced preservative exposure, preservative-free delivery, reliable sterile supply, improved drop control, or packaging that supports better in-use contamination control.
References
-
U.S. Food and Drug Administration. (n.d.). Polytrim: Polymyxin B sulfate and trimethoprim sulfate ophthalmic solution, prescribing information. Drugs@FDA and product labeling.
-
U.S. Food and Drug Administration. (2013). Guidance for industry: ANDAs for certain highly purified synthetic peptide drug products that reference listed drugs of recombinant origin. FDA.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.
-
U.S. Food and Drug Administration. (2023). Ophthalmic drug products for topical ophthalmic administration: Quality considerations. FDA.
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. FDA.
-
U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).
